Antigen-presenting molecules, encoded by the major histocompatibility complex (MHC) and CD1 family, bind peptideand lipid-based antigens, respectively, for recognition by T cells. Mucosal-associated invariant T (MAIT) cells are an abundant population of innate-like T cells in humans that are activated by an antigen(s) bound to the MHC class I-like molecule MR1. Although the identity of MR1-restricted antigen(s) is unknown, it is present in numerous bacteria and yeast. Here we show that the structure and chemistry within the antigen-binding cleft of MR1 is distinct from the MHC and CD1 families. MR1 is ideally suited to bind ligands originating from vitamin metabolites. The structure of MR1 in complex with 6-formyl pterin, a folic acid (vitamin B9) metabolite, shows the pterin ring sequestered within MR1. Furthermore, we characterize related MR1-restricted vitamin derivatives, originating from the bacterial riboflavin (vitamin B2) biosynthetic pathway, which specifically and potently activate MAIT cells. Accordingly, we show that metabolites of vitamin B represent a class of antigen that are presented by MR1 for MAIT-cell immunosurveillance. As many vitamin biosynthetic pathways are unique to bacteria and yeast, our data suggest that MAIT cells use these metabolites to detect microbial infection.
. The constrained gene usage of the MAIT-cell antigen receptor (MAIT TCR), which is distinct from that of the NKT-cell antigen receptor (Va24Ja18-Vb11 in humans), suggests that MAIT cells target a key, albeit limited and atypical, class of antigen 6 . Providing further evidence for highly conserved MAIT ligand(s), mutagenesis studies of MAIT TCRs with different Vb segments showed that a cluster of conserved TCR residues is crucial for MAIT TCR recognition of diverse microbes 9 . The MAIT TCR is restricted to the monomorphic MHC class I (MHC-I)-like related molecule (MR1), which is highly conserved in mammals and encoded by a single gene that is not associated with the MHC [11] [12] [13] . MR1 transcripts are ubiquitously expressed in all cell types, and the MR1 primary structure is highly conserved across species, thereby suggesting a key, evolutionarily conserved function for MR1 in immunity 13, 14 . Endogenous cell surface expression levels of MR1 are typically very low, suggesting that quantitatively limiting antigen(s) may be required to increase MR1 presentation 12, 15 . MR1 shares considerable sequence similarity with the MHC-I and CD1 familiesantigen-presenting molecules that are ideally suited to bind peptideand lipid-based antigens, respectively. However, the precise identity of the MR1-restricted antigen(s), representing an important question in MAIT-cell biology, is unknown.
Identification of an MR1-restricted ligand
Yeast and many, but not all, bacterial species can activate MAIT cells in an MR1-restricted manner, suggesting that a closely related series of antigen(s) common to these microbes specifically bind MR1 (ref. 3) . MHC-I and MHC-I-like molecules are usually stable only in the presence of ligand, and so, unsurprisingly, MR1 could not be refolded efficiently in refolding buffer alone, consistent with MR1 requiring a specific antigen(s) for its assembly and stability (not shown). Reasoning that recovery of properly assembled MR1-b2-microglobulin (b2m) complexes would indicate efficient capture of a ligand(s), we established refolds of denatured human MR1 and b2m with different sources of candidate ligands, including lipid-based ligands that were previously proposed to bind MR1 (ref. 16 ). Refolding in the cell culture medium RPMI-1640 (a control) enhanced the yield of MR1-b2m complexes, suggesting the presence of trace amounts of MR1 ligand(s) in this medium. RPMI-1640 is a defined culture medium containing several vitamin supplements, some of which are uniquely synthesized in bacteria and plants, but not mammals. Hence, we tested the refolding of MR1 in the presence of various vitamin sources. We observed that folic acid sources (including RPMI-1640 medium, vitamin B complex tablets, or folic acid itself) all notably enhanced yields of MR1 purified by subsequent chromatographic steps (Fig. 1a) . The chromatographic properties of the refolded MR1-antigen closely matched those of refolded peptide-MHC-I (ref. 17) , with a molecular mass of approximately 44 kDa, consistent with a monomeric MR1-b2m complex (Fig. 1a) . Moreover, the refolded material reacted with an anti-MR1 monoclonal antibody (Fig. 1b) , indicating that a vitamin-derived compound(s) enabled the proper refolding of MR1.
Analysis of MR1 refolded with folic acid by negative mode electrospray ionization-time-of-flight mass spectrometry (ESI-TOF-MS), exclusively revealed a ligand with a mass to charge (m/z) ratio of 190.03. Comparison of this species with the Scripps Metlin metabolite mass spectrometry database (http://metlin.scripps.edu/), as well as further tandem mass spectrometry analysis, suggested that this species was 6-formyl pterin (6-FP) (Fig. 1c, d ). ESI-TOF-MS analysis of MR1 refolded with pure, chemically synthesized 6-FP showed an identical species to that found in MR1 refolded with folic acid (Fig. 1d) . The species giving m/z 190.03 by ESI-TOF analysis of 6-FP and MR1-6-FP had identical liquid chromatography retention times and product ions after tandem mass spectrometry analysis ( Fig. 1d and Supplementary Fig. 1 ). Notably, 6-FP is produced by the photodegradation of folic acid 18 , and folic acid contained trace amounts of 6-FP as measured by ESI-TOF-MS. Moreover, chromatographically purified folic acid that was depleted of 6-FP, and subsequently promptly used for refolding with MR1, still yielded the MR1-6-FP complex (data not shown), indicating that photodegradation of folic acid was rapid. Furthermore, 6-FP specifically upregulated cell surface expression of MR1 on human lymphoid C1R cells (Supplementary Fig. 2 ). These studies provided evidence that MR1 can bind to small molecule organic compounds, such as 6-FP, that are derived from vitamin metabolism.
The structure of MR1-antigen
To gain insight into the detailed architecture of the MR1 molecule, we expressed and refolded MR1 in complex with 6-FP and subsequently 
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determined the structure of the MR1-6-FP complex (Supplementary Table 1 and Supplementary Fig. 3 ) and compared it with representative peptide-and lipid-binding antigen-presenting molecules, namely HLA-A2 and CD1d, respectively. MR1 adopted a standard MHC-I fold (Fig. 2a) 19, 20 . MR1 was most closely related to an avian monomorphic MHC-I like molecule (43% sequence identity, r.m.s.d. 1.77 Å over 276 Ca atoms) that is thought to bind non-peptide-based antigens 21 ( Supplementary Fig. 4 ). The a1-a2 domains formed the MR1 antigen-binding cleft, which comprises two long a-helices sitting atop a b-sheet, akin to HLA-A2 and CD1d (Fig. 2b) . The helices of the MR1 antigen-binding cleft were not closely juxtaposed, as was observed for the human hemochromatosis (HFE) protein, an MHC-I-like molecule that does not bind antigen 22 ( Fig. 2b) . Indeed, the positioning of the a1 and a2 helices of MR1 more closely resembled HLA-A2 than that of the more constricted CD1d antigen-binding cleft (r.m.s.d. 1.0 Å over 133 Ca atoms and 3.1 Å over 99 Ca atoms, respectively) ( Fig. 2b) . However, the central cleft of MR1 is not suited, either chemically or structurally, to accommodate peptide-or lipid-based antigens (Fig. 3a) . Namely, the HLA-A2 cleft is solvent exposed and mostly polar, thereby ideally suited for binding peptides 23 ; whereas the CD1d cleft binds lipids by means of a hydrophobic-lined cavity shielded from solvent 20 . By comparison, the MR1 antigen-binding cleft was mostly solvent exposed, consisting of a mixture of charged and hydrophobic residues, of which a preponderance of aromatic residues within the a1 and a2 helices was evident ( Fig. 3a and Supplementary Fig. 5 ). Furthermore, the central cavity of MR1 (760 Å 3 ) was much smaller than that of CD1d (1,690 Å 3 ) 20 ( Fig. 3b ). Although MHC-I molecules contain a conserved network of residues at the amino-and carboxy-terminal ends of the antigen-binding groove that tethers the termini of antigenic peptides 23 , the corresponding locations within the MR1 cleft, although showing some conservation, were different from MHC-I (Fig. 3c) . Furthermore, the end of the MR1 groove is not 'open', as observed for MHC class II molecules 24 . Whereas MHC-I comprises six pockets that accommodate the side chains of the peptide, these are not present in MR1 (ref. 25) . Instead, a large number of bulky side chains occupied the entire length and breadth of the cleft, and it is this architecture that probably prevented the helical jaws of MR1 packing closely together (Fig. 3c) . Accordingly, the structure and chemical properties of the MR1 antigen-binding cleft were distinct from that of peptide-and lipid-based antigen-presenting molecules.
Mode of MR1-antigen presentation 6-FP was located centrally within the MR1 cleft, positioned towards the base of the b-sheet (Figs 2a and 3d) . The pterin ring lies relatively flat against the b-sheet, and in a different location to abacavir, a bicyclic compound recently found to bind HLA-B*57:01 (ref. 26) (Supplementary Fig. 6 ). 6-FP exhibited very limited solvent accessibility, with 317 Å 2 of the available 327 Å 2 being buried by MR1 (Fig. 3a) . Binding to 6-FP was dominated by hydrophobic interactions, with Tyr 7, Tyr 62, Trp 69 and Trp 156 forming an 'aromatic cradle' that sequestered the ligand. In addition, the ligand formed van der Waals interactions with Arg 9, Arg 94, Ile 96 and Gln 153 (Fig. 3d ) (Supplementary Table 2 ). Notably, a previous mutational study on MR1 implicated Tyr 7, Arg 9 and Arg 94 in MAIT-cell activation 11 . There was clear evidence for a covalent bond between the Lys 43 Nf and the formyl group of 6-FP ( Supplementary Fig. 3 ), indicating that, during purification and/or crystallization, Lys 43 had formed a Schiff base with the formyl group. An engineered Lys43Arg MR1 mutation failed to refold in the presence of 6-FP (not shown), highlighting the importance of the Lys 43-6-FP interaction. Adjacent to the MR1-antigen-binding pocket there were two positively charged residues (Arg 9 and Arg 94) protruding up into the cleft, suggesting a requirement for polar moieties in other potential MR1-restricted ligands. Of note, the residues in contact with 6-FP (and the two Arg residues) are conserved across MR1 from all species ( Supplementary Fig. 7 ), suggesting that recognition of ligands within the MR1-binding pocket is highly conserved. Hence, the structure of the MR1-6-FP complex shows how MR1 is ideally suited to present small organic compounds that can originate from vitamins.
MR1-restricted MAIT activation
Although 6-FP is a ligand for MR1, it did not activate Jurkat cells transduced with a MAIT TCR (termed Jurkat.MAIT cells) (Fig. 4a) MR1 is in cyan; HFE is in yellow; MHC-I is in red; CD1d is in magenta.
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primary MAIT cells (Fig. 5c, e) , suggesting pterin analogues might provide a basic structural scaffold for another ligand, or class of ligand, capable of activating MAIT cells. Notably, antigen-presenting cells transfected with MR1 and infected with Salmonella typhimurium specifically activated Jurkat.MAIT cells 9 , but not Jurkat cells expressing a control MHC-restricted TCR ( Supplementary Fig. 8a, b) . Furthermore, we found that the supernatant from S. typhimurium was able to activate Jurkat.MAIT and MAIT cells (Figs 4a and 5a-c, e) , and we reasoned that identification of the bacterial-activating ligand(s) from S. typhimurium supernatant might be facilitated, if MR1-b2m could be refolded in supernatant from Salmonella grown in M9 minimal media lacking vitamin supplements and their derivatives, which might compete for MR1 binding. Therefore we refolded MR1 and searched for ligands that complexed with MR1 only in supernatant from Salmonella grown in minimal medium. Using this approach, a single compound at m/z 329.1100 was identified by high-resolution ESI-TOF-MS. This was exclusively present in MR1 refolded in the presence of supernatant of Salmonella grown in M9 minimal media (that is, lacking vitamin supplements) (Fig. 4b, c) . Other MR1 ligands specifically derived from the Salmonella supernatant were not identified in the mass range from 50 to 1,000 AMU (Supplementary Fig. 9 ). This compound was assigned an unambiguous atomic composition of C 12 H 18 N 4 O 7 on the basis of both its molecular ion and its component isotopic mass distribution pattern. A search for potential matching compounds suggested one of the derivatives of riboflavin (vitamin B2); reduced 6-hydroxymethyl-8-Dribityllumazine (rRL-6-CH 2 OH) (C 12 H 18 N 4 O 7 ), 7-hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-7-OH) (C 12 H 16 N 4 O 7 ) and its precursor, 6,7-dimethyl-8-D-ribityllumazine (RL-6,7-diMe) (C 13 H 16 N 4 O 6 ) are candidate MAIT-activating ligands (Fig. 4d) .
To establish formally whether rRL-6-CH 2 OH, RL-6-Me-7-OH and/ or RL-6,7-diMe represented MR1 ligands and could activate MAIT cells, we chemically synthesized and biochemically characterized these compounds. Analysis by ESI-TOF-MS of pure, chemically synthesized rRL-6-CH 2 OH exclusively revealed a species identical to that found in MR1 refolded with Salmonella supernatant (Fig. 4b, c) . Namely, ESI-TOF analysis identified a species with an m/z ratio of 329.1100 in the MR1 Salmonella supernatant that matched precisely with synthetic rRL-6-CH 2 
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). Moreover, they showed identical isotopic mass distribution patterns (confirming atomic composition), identical fragmentation patterns by tandem mass spectrometry analysis, and had identical liquid chromatography-mass spectrometry (LC-MS) column retention times (Fig. 4b-d) . The structures of tandem mass spectrometry fragment ions provide important evidence for the assigned structure of rRL-6-CH 2 OH, which undergoes dehydration/tautomerism to give m/z 311.1052 (6-methyl-8-D-ribityllumazine) or sequential dehydration/ribityl side-chain scission to give m/z 191.0586 (Fig. 4c, d) . The structures of rRL-6-CH 2 OH, RL-6-Me-7-OH and RL-6,7-diMe are closely related to 6-FP, but possess an extra ribityl moiety that, based on the crystal structure of MR1-6-FP, may permit direct contact by the MAIT TCR. Notably, these compounds are derived from the riboflavin biosynthetic pathway present in most, but not all, bacteria and yeast (Supplementary Table 3) .
We tested the ability of these compounds to activate Jurkat.MAIT cells and human MAIT cells from peripheral blood (Fig. 5) . Although the ribityl lumazines failed to activate the control Jurkat.LC13 cell line in the presence of MR1-expressing C1R cells (Fig. 5a) , they specifically activated three Jurkat.MAIT-cell lines (transduced with TRBV6.1, TRBV6.4 and TRBV20 MAIT TCRs) in the presence of C1R cells expressing MR1 (Fig. 5a ), whereas riboflavin did not (not shown). An anti-MR1 blocking monoclonal antibody 11 specifically inhibited the riboflavin metabolite-mediated Jurkat.MAIT activation (Fig. 5b and Supplementary Fig. 10) , and rRL-6-CH 2 OH upregulated MR1 cell surface expression on C1R cells (Supplementary Fig. 2 ). All compounds specifically activated freshly isolated MAIT cells as defined by (Fig. 5c -e and Supplementary Figs 11 and 12 ). Activation was assayed by CD69 upregulation (Fig. 5c, d ) and intracellular cytokine staining for interferon (IFN)-c and tumour necrosis factor (TNF) (Fig. 5e) . Notably, rRL-6-CH 2 OH, although closely related to RL-6-Me-7-OH and RL-6,7-diMe, was a much more potent MAIT agonist as judged by Jurkat.MAIT-cell and MAIT-cell activation. This indicates that there are several riboflavin-based metabolites that exhibit a broad spectrum in their ability to activate MAIT cells. The enzymatic pathway that generates these riboflavin precursors only seems to be found in 
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microbes that are capable of activating MAIT cells and is absent in non-activating microbes (Supplementary Table 3 ). Accordingly, direct precursors and metabolites of riboflavin biosynthesis clearly activate MAIT cells.
Discussion
T cells expressing ab TCRs interact with diverse antigens presented by MHC-I and MHC-I-like molecules 27 . Indeed, the cellular arm of the immune system uses an array of polymorphic and monomorphic antigen-presenting molecules to provide collectively broad awareness of signature microbial products with distinct chemistries, thereby enabling self from non-self discrimination and facilitating protective immunity. Our findings provide evidence that this antigenic arsenal is extended by the capacity of MR1 to present small organic compounds derived from biosynthetic intermediates to, or chemical metabolites of, endogenously synthesized vitamins.
MAIT cells are activated, in an MR1-dependent manner, by a broad spectrum of bacteria and yeast, but not by viruses or certain bacteria 3 . Although a folic acid (vitamin B9) derivative (6-FP) could bind MR1, it was non-stimulatory for MAIT cells, suggesting that this ligand represents a structural scaffold for binding MR1, but requires a further moiety to engender MAIT-cell activation. Accordingly, we showed that riboflavin (vitamin B2) derivatives, larger in size but closely related structurally to 6-FP, could bind MR1 and activate MAIT cells. A key distinction between the microbes that are stimulatory and non-stimulatory to MAIT cells is that the former synthesize riboflavin, whereas the latter do not. These observations suggest a mode by which MAIT cells might sense microbial infection or RESEARCH ARTICLE overgrowth at mucosal sites in an MR1-restricted manner. Of note, these vitamin-based metabolites are secreted and are diffusible, suggesting a mechanism by which MAIT cells might sense bacterial activity across mucosal membranes potentially regulating local immunity and mucosal barrier functions. Our findings highlight that bacterially produced vitamin-based metabolites can exhibit a broad spectrum of MAIT-cell activation. Indeed, the identification of both activating and non-activating MR1 ligands suggests competition between these agents thus modulating MAIT-cell activity in the context of bacterial infection. Moreover, as the pterin ring occurs widely in nature, and represents a common scaffold of small molecule therapeutics, it will be of interest to establish whether the MAIT cell-MR1 axis is perturbed in any pathological or drug-induced conditions; how diet can influence MAIT activity; and whether other microbial metabolites represent MAIT-cell ligands capable of modulating the function of these cells. Clearly, there is a close relationship between the human immune system, host fitness and gut microbiota metabolites [28] [29] [30] . Defining MAIT-cell-activating ligands represents a fundamental new advance that will be pivotal in understanding the physiological and pathological role of MAIT cells, a very abundant population of innate-like T cells associated with the gastrointestinal mucosa. Our findings also suggest that other microbial-specific metabolites 30 may serve as molecular signatures of microbial infection that undergo immunosurveillance.
METHODS SUMMARY
Refolding MR1 with 6-FP. This was performed using a method similar to that established for MHC-I refolding. Synthesized 6-FP and 6,7-dimethyl-pterin were purchased from Schirks Laboratories, folic acid was purchased from SigmaAldrich. Further details are provided in the Methods. Analysis of MR1-6-FP by mass spectrometry. MR1-6-FP (4 mg) was loaded onto an XBridge C18 reversed phase column (Waters) in 20 mM ammonium acetate, pH 5.4, buffer, and detected in an Agilent ESI-TOF mass spectrometer after elution in an acetonitrile gradient. Data was collected in negative ion mode. Synthetic 6-FP (0.4 mg) was analysed under the same conditions. Crystallization and data collection. The MR1-6-FP complex was crystallized and the structure determined as described in the Methods. Analysis of MR1-bacterial supernatant by mass spectrometry. See Methods for full details. Synthesis of MR1 antigens. Chemical synthesis of RL-6,7-diMe, RL-6-Me-7-OH and reduced rRL-6-CH 2 OH is described in Methods and Supplementary Fig. 13 . Activation of Jurkat.MAIT and MAIT cells. The activation of Jurkat.MAIT cells was performed as described 9 . Further details are provided in the Methods.
